Even though a large number of studies have focused on teasing out the role of neoantigen-targeted CD8+ T cell activity in cancer, significant and preferential CD4+ T cell activation by neoantigens have been recognized in multiple pre-clinical and clinical studies (175). The gene discussed is CD8A; the disease is cancer.